title: Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.
abstract: SUMMARY: The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUC1 conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On this basis, three phase I trials were performed in patients with adenocarcinoma to evaluate the tnxicity and the immunologic responses to mannan MUC1. Forty-one patients with metastatic or locally advanced carcinoma of the breast (trial 1), colon (trial 2), and various adenocarcinomas (trial 3) received increasing doses of M-FP (1 to 300 &mgr;g). The immunizations were given at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide (to increase cellular immunity) was given on weeks 1 and 4. M-FP was given intramuscularly in trial 1 and intraperitoneally in trial 2. No toxic effects occurred, and delayed-type hypersensitivity responses were present only as a microscopic lymphocytic infiltration. Overall, approximately 60% of the patients had high-titer MUC1 immunoglobulin G1 antibody responses, with the intraperitoneal route yielding approximately 10-fold higher responses. Cellular responses (proliferation, cytotoxic T cells, or CD8 T cells secreting tumor necrosis factor-alpha alphand interferon-gamma in response to MUC1 stimulation in vitro) were found in 28% of the patients, which was similar to that seen without cyclophosphamide. In most patients, disease progressed, but in five it remained stable. In addition, there were no objective responses. M-FP is not toxic and induces immune responses that were amplified by the intraperitoneal route of immunization. Cyclophosphamide was of no benefit.
authors.affiliation: Dr. Karanikas' current address is Ludwig Institute for Cancer Research, Avenue Hippocrate 74, B.7459, B-1200 Brussels, Belgium.
authors.forename: Vaios
authors.initials: V
authors.lastname: Karanikas
authors.forename: Grenville
authors.initials: G
authors.lastname: Thynne
authors.forename: Paul
authors.initials: P
authors.lastname: Mitchell
authors.forename: Chin-Swee
authors.initials: CS
authors.lastname: Ong
authors.forename: Dishan
authors.initials: D
authors.lastname: Gunawardana
authors.forename: Robert
authors.initials: R
authors.lastname: Blum
authors.forename: Julian
authors.initials: J
authors.lastname: Pearson
authors.forename: Jodie
authors.initials: J
authors.lastname: Lodding
authors.forename: Geoff
authors.initials: G
authors.lastname: Pietersz
authors.forename: Russell
authors.initials: R
authors.lastname: Broadbent
authors.forename: Brian
authors.initials: B
authors.lastname: Tait
authors.forename: Ian F. C.
authors.initials: IF
authors.lastname: McKenzie